HOPKINTON, Mass., July 9, 2024
/PRNewswire/ -- Phosphorex, a drug delivery-focused contract
development and manufacturing organization ("CDMO"), is pleased to
announce the appointment of John
Rigg to its Board of Directors. Mr. Rigg is currently CEO of
NanoImaging Services ("NIS"), a leading provider of cryo-electron
microscopy services. Phosphorex and NIS are both Ampersand Capital
Partners portfolio companies.
"I am honored to join the Board of
Directors at Phosphorex at such a pivotal time as the
nanoparticle-based drug delivery market is gaining great
traction..."
This appointment marks a significant addition to the company's
leadership team as Mr. Rigg brings a wealth of experience from the
pharmaceutical and biomanufacturing industries. With a
distinguished career spanning over 25 years, Mr. Rigg has
demonstrated exceptional leadership and strategic vision within
operations, manufacturing, and general management of several
biopharmaceutical companies, including Exelead Biopharma,
Sigma-tau, Ventria Bioscience, and Eli Lilly & Company.
"We are thrilled to welcome John to our Board of Directors,"
said Jarlath Keating, CEO of
Phosphorex. "John's extensive experience and proven track record in
the Pharma & Biotech industry will be invaluable as we take the
next steps in establishing clinical manufacturing capabilities and
broadening our array of services. We look forward to John's
contributions in guiding our strategic direction and growth."
On his Board appointment, Mr. Rigg comments, "I am honored to
join the Board of Directors at Phosphorex at such a pivotal time as
the nanoparticle-based drug delivery market is gaining great
traction. I look forward to working with this talented team to
further Phosphorex's success."
About Phosphorex
Phosphorex is a leading provider of
drug delivery technologies and solutions. By harnessing the
potential of microspheres and nanoparticles for drug delivery,
Phosphorex offers tailored solutions and enabling technologies to
optimize a drug's release rate, targeting ability, bioavailability,
and deliverability, with the goal of achieving desired therapeutic
effects while reducing adverse clinical outcomes. Phosphorex
supports pharmaceutical and biotech companies through all phases of
their development, from proof of concept to clinical studies.
Phosphorex's mission is to help our partners solve complex problems
and develop successful drugs to help patients. Additional
information about Phosphorex is available at www.phosphorex.com or
follow us on LinkedIn.
About Ampersand Capital Partners
Founded in 1988,
Ampersand Capital Partners is a middle market private equity firm
with $3 billion of assets under
management dedicated to growth-oriented investments in the
healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a
unique blend of private equity and operating experience to build
value and drive long-term performance alongside its portfolio
company management teams. Ampersand has helped build numerous
market-leading companies across each of the firm's core healthcare
sectors. For additional information, visit www.ampersandcapital.com
or follow us on LinkedIn.
CONTACT: Kim Yang
Director of Marketing
kyang@phosphorex.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/phosphorex-appoints-john-rigg-to-board-of-directors-302191921.html
SOURCE Phosphorex LLC